Intensive Care Medicine

, Volume 33, Issue 10, pp 1815–1818

A primer on data safety monitoring boards: mission, methods, and controversies

  • Lisa K. Hicks
  • Andreas Laupacis
  • Arthur S. Slutsky
Legal and Ethical issues in clinical research

References

  1. 1.
    Heart Special Project Committee (1988) A report from the heart special project committee to the national advisory heart council, May 1967. Controlled Clin Trials 9:137–148CrossRefGoogle Scholar
  2. 2.
    Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA (1998) Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial JAMA 280:159–165PubMedCrossRefGoogle Scholar
  3. 3.
    Steinbrook R (2003) Trial design and patient safety—the debate continues. N Engl J Med 349:629–630PubMedCrossRefGoogle Scholar
  4. 4.
    EMEA Committee for Medicinal Products for Human Use (2005) Guideline on data monitoring committees. Available at: http://www.emea.eu.int/pdfs/human/ewp/587203en.pdf, accessed 16 April 2007
  5. 5.
    Grant AM, Altman DG, Babiker AB, Campbel MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MKB, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AF, Wallace SA, the DAMOCLES study group (2005) Issues in data monitoring and interim analysis of trials. Health Technol Assess 9:1–235Google Scholar
  6. 6.
    United States Department of Health and Human Services, Food and Drug Administration (2006) Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. Available at: http://www.fda.gov/CBER/gdlns/clintrialdmc.pdf, accessed 16 April 2007
  7. 7.
    United States Department of Health and Human Services, Food and Drug Administration (2006) Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. http://www.fda.gov/CBER/gdlns/clintrialdmc.pdf, p 1, accessed 16 April 2007
  8. 8.
    Goss PE, Ingle JF, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 39:1793–1802CrossRefGoogle Scholar
  9. 9.
    Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH (2005) Randomized trials stopped early for benefit: a systematic review JAMA 294:2203–2209PubMedCrossRefGoogle Scholar
  10. 10.
    Pocock SJ (2004) A major trial needs three statisticians: why, how and who? Stat Med 23:1535–1539PubMedCrossRefGoogle Scholar
  11. 11.
    Snapinn S, Cook T, Shapiro D, Snavely D (2004) The role of the unblinded sponsor statistician. Stat Med 23:1531–1533PubMedCrossRefGoogle Scholar
  12. 12.
    Grant AM, Altman DG, Babiker AG, Campbell MK, the DAMOCLES Study Group (2005) A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 365:711–722Google Scholar
  13. 13.
    Slovic P (1987) Perception of risk. Science 236:280–285PubMedCrossRefGoogle Scholar
  14. 14.
    Whitehead J (2004) Stopping clinical trials by design. Nat Rev Drug Discov 3:973–977PubMedCrossRefGoogle Scholar
  15. 15.
    Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bev M, Shearer W, Jacobson RL et al (1994) Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 331:1173–1180PubMedCrossRefGoogle Scholar
  16. 16.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Stat M, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102PubMedCrossRefGoogle Scholar
  17. 17.
    Solomon SD, McMurray JJ, Pfeffer MA, Whittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M for the Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRefGoogle Scholar
  18. 18.
    Arber N, Eagle CJ, Spicak J, Raez I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonal K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, for the PreSAP Trial Investigators (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895PubMedCrossRefGoogle Scholar
  19. 19.
    Fleming TR, Ellenberg S, DeMets DL (2002) Monitoring clinical trials: issues and controversies regarding confidentiality. Stat Med 21:2843–2851PubMedCrossRefGoogle Scholar
  20. 20.
    Lilford RJ, Braunholtz D, Edwards S, Stevens A (2001) Monitoring clinical trials—interim data should be publicly available. BMJ 323:441–442PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Lisa K. Hicks
    • 1
    • 2
    • 3
  • Andreas Laupacis
    • 2
  • Arthur S. Slutsky
    • 2
    • 3
  1. 1.Department of Medicine, Division of Oncology/HematologySunnybrook Health Sciences Centre, University of TorontoTorontoCanada
  2. 2.Keenan Research Centre, Li Ka Shing Knowledge InstituteSt. Michael’s HospitalTorontoCanada
  3. 3.Faculty of MedicineUniversity of TorontoTorontoCanada

Personalised recommendations